Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Cytovation logo — Creating transformative medicines for patients with cancer

Cytovation

Creating transformative medicines for patients with cancer

Founded 2015 Norway Norway 11 employees Series A Total: $285.00M Biotechnology, Life Sciences

General Information

Company Name Cytovation
Founded Year 2015
Location Norway Norway +1
Founders / Decision Makers
Team member
Employees 11
Industries Biotechnology, Life Sciences
Funding Stage Series A
Social

Get notified when Cytovation moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Cytovation

Cytovation ASA is a biotechnology startup based in Norway, with a vision to revolutionize cancer treatment. Its lead asset, CyPep-1, is a synthetic peptide designed to target tumor cells with a dual mechanism of action. This includes direct tumor-specific membrane lysis and in-situ vaccination, as well as immune activation through inhibition of the β-catenin pathway. Having showcased strong First in Human (FIH) clinical data, the company received a significant kr85.00M Series A investment on 2nd June 2023 from investors Canica and Project Sandwater. With this backing, Cytovation is focused on advancing CyPep-1 to Proof of Concept (POC) and pivotal clinical development, with a specific emphasis on β-catenin-driven cancers. Cytovation's commitment to creating transformative medicines for cancer patients positions it as an innovative and promising player in the immuno-oncology space.

Taxonomy: immuno-oncology, biotech, clinical stage, immunotherapy, synthetic peptide, tumor-specific, solid tumors, in-situ vaccination, immune activation, β-catenin pathway, clinical development, cancer treatment, oncology, pharmaceuticals

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 2
Investor
•••• •••• 		02 Jun 2023
Series A •••••• 2
Investor
•••• •••• 		25 Jan 2022
Venture Round •••••• - 29 Jun 2017

Cytovation Alternatives & Competitors

Cytovation vs
TME Pharma
TME Pharma Germany

Developing novel therapies for treatment of the most aggressive cancers by acting on the tumor micro...

Post Ipo Equity
12 employees
Biotechnology, Health Care
Cytovation vs
Yino
Yino

Advancing Oncology Radiotherapy with Pioneering Clinical Technology

Series C
IT, Information Technology
Cytovation vs
Farcast Biosciences
Farcast Biosciences India

24,000 human tumors and counting - building the most precise functional precision tumor microdynamic...

Pre Seed
38 employees
Biotechnology, Health Care

FAQ About Cytovation

Creating transformative medicines for patients with cancer
Cytovation was founded in 2015.
Cytovation is headquartered in Norway.
Cytovation operates in the following industries: Biotechnology, Life Sciences.
Cytovation has approximately 11 employees.
Cytovation has completed 3 funding rounds, raising a total of $285.00M. The latest funding stage is Series A.
Top alternatives and competitors to Cytovation include TME Pharma, Yino, Farcast Biosciences, HiberCell, SELLAS Life Sciences Group, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cytovation and TME Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Cytovation and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy